Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Arpida closes CHF51.3mm third round; then an additional CHF33mm

Executive Summary

Arpida Ltd. (develops anti-infectives) closed its third financing round, bringing in CHF51.3mm ($39mm). Returning investors Alta Berkeley, Aventic Partners, BioMedinvest, CDC IXIS Innovation, HBM BioVentures, HealthCap, 3i, and Partners Group were joined by Swissfirst Bank, Temasek Holdings, Carnegie Fund, CDIB Bioscience Ventures, CITA, MVI Finance, Schroder ISF, and other institutional and private investors.
Deal Industry
  • Pharmaceuticals
  • Biotechnology
    • Drug Discovery Tools
      • Genomics-Proteomics
Deal Status
  • Final
Deal Type
  • Financing
    • Venture Financing

Related Companies